Overexpression of SLC38A1 is associated with poorer prognosis in Chinese patients with gastric cancer

BMC Gastroenterology

Jie-jun Wang²  Ling-Yan Yuan²  Jian-xin Qian²  Hui-feng Gao¹  Ping Li³  Jing Xie¹ 

[1] Department of Integrative Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, 270 DongAn Road, Shanghai 200032, China;Department of oncology, Changzheng Hospital, the Second Military Medical University, 64 HeTian Road, Shanghai 200003, China;Stem Cell Research Center, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China

关键词: Prognostic factor;    SLC38A1;    Immunohistochemistry;    Tissue microarray;    Gastric cancer;   

Others  :  855635
DOI  :  10.1186/1471-230X-14-70

 received in 2013-04-10, accepted in 2014-03-31,  发布年份 2014

【 摘 要 】

Background

Current literature has demonstrated that host glutamine depletion facilitates tumorigenesis. Likewise, the glutamine transporter SLC38A1 is putatively associated with malignant transformation and tumor progression. Taken together, this forms the premise for undertaking the current study. The twofold aim of this study was to provide insight into whether or not a variance in the expression of SLC38A1 exists between human gastric cancer and healthy human tissues, and to determine how silencing the SLC38A1 gene could affect the proliferation, viability, migration, and invasion of gastric cancer cells.

Methods

Immunohistochemical staining was used to analyze the expression of SLC38A1 in gastric cancer tissues and adjacent healthy mucosa in 896 patients with pathologically confirmed gastric cancer who had underwent R0 resection. SH-10-TC cells (a gastric cancer cell line) were used to examine whether silencing SLC38A1 with siRNA could affect cell viability, migration and invasion.

Results

The SLC38A1 protein was very low or undetectable in healthy gastric mucosa. In contrast, strong staining of SLC38A1 protein was found in the cytoplasm in 495 out of the 896 gastric cancer samples. More pronounced SLC38A1 expression in gastric cancer tissues was significantly associated with age, differentiation status, lymph node metastasis, TNM stage and PCNA (proliferating cell nuclear antigen) expression. Upon univariate survival analysis, SLC38A1 expression was correlated with poor survival. Multivariate survival analysis revealed that SLC38A1 was an independent prognostic factor.

Conclusion

SLC38A1 is overexpressed in gastric cancer, which suggests that it is contributory to tumor progression. These results encourage the exploration of SLC38A1 as a target for intervention in gastric cancer.

【 授权许可】

   
2014 Xie et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]McGivan JD, Pastor-Anglada M: Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 1994, 299:321-334.
• [2]Lin J, Raoof DA, Thomas DG, Greenson JK, Giordano TJ, Robinson GS, Bourner MJ, Bauer CT, Orringer MB, Beer DG: L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia 2004, 6:74-84.
• [3]Kim DK, Ahn SG, Park JC, Kanai Y, Endou H, Yoon JH: Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precusorlesions. Anticancer Res 2000, 24:1671-1675.
• [4]Haase C, Bergmann R, Fuechtner F, Hoepping A, Pietzsch J: L-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18 F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J Nucl Med 2007, 48:2063-2071.
• [5]Campbell WA, Thompson NL: Overexpression of LAT1/CD98 light chain is sufficient to increase system L-amino acid transport activity in mouse hepatocytes but not fibroblasts. J Biol Chem 2001, 276:16877-16884.
• [6]Kondoh N, Imazeki N, Arai M, Hada A, Hatsuse K, Matsuo H, Matsubara O, Ohkura S, Yamamoto M: Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues. Int J Oncol 2007, 31:81-87.
• [7]Wu Y, Shen D, Chen Z, Clayton S, Vadgama JV: Taxol induced apoptosis regulates amino acid transport in breast cancer cells. Apoptosis 2007, 12:593-612.
• [8]Novak D, Quiggle F, Haafiz A: Impact of forskolin and amino acid depletion upon System A activity and SNAT expression in BeWocells. Biochimie 2006, 88:39-44.
• [9]Sugawara M, Nakanishi T, Fei YJ, Huang W, Ganapathy ME, Leibach FH, Ganapathy V: Cloning of an amino acid transporter with functional characteristics and tissue expression pattern identical to that of system A. J Biol Chem 2000, 275:16473-16477.
• [10]Varoqui H, Zhu H, Yao D, Ming H, Erickson JD: Cloning and functional identification of a neuronal glutamine transporter. J Biol Chem 2000, 275:4049-4054.
• [11]Hatanaka T, Huang W, Ling R, Prasad PD, Sugawara M, Leibach FH, Ganapathy V: Evidence for the transport of neutral as well as cationic amino acids by ATA3, a novel and liver-specific subtype of amino acid transport system A. Biochim Biophys Acta 2001, 1510:10-17.
• [12]Liu K, Wang G, Ding H, Chen Y, Yu G, Wang J: Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer 2010, 10:428.
• [13]Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 2009, 15:1821-1829.
• [14]Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, Xie K: Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis 2008, 25:695-702.
• [15]Yu GZ, Chen Y, Wang JJ: Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009, 135:1331-1339.
• [16]Yu WL, Cong WM, Zhang Y, Chen Y, Wang F, Yu G: Overexpression of ATA1/SLC38A1 predicts future recurrence and death in Chinese patients with hilarcholangiocarcinoma. J Surg Res 2011, 171:663-668.
• [17]Peng Z, Wei D, Wang L, Tang H, Zhang J, Le X, Jia Z, Li Q, Xie K: RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res 2006, 12:6386-6394.
• [18]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
• [19]Yuneva M: Finding an "Achilles' heel" of cancer: the role of glucose and glutamine metabolism in the survival of transformed cells. Cell Cycle 2008, 7:2083-2089.
• [20]Viallard V, Denis C, Trocheris V, Murat JC: Effect of glutamine deprivation and glutamate or ammonium chloride addition on growth rate, metabolism and differentiation of human colon cancer cell-line HT29. Int J Biochem 1986, 18:263-269.
• [21]Medina MA, Sánchez-Jiménez F, Márquez J, Rodríguez-Quesada A, Nuñez-De-Castro I: Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem 1992, 113:1-15.
• [22]DeBerardinis RJ, Cheng T: Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29:313-324.
• [23]Kaelin WG Jr, Thompson CB: Q&A: Cancer: clues from cell metabolism. Nature 2010, 465:562-564.
• [24]Weiss MD, Derazi S, Rossignol C, Varoqui H, Erickson JD, Kilberg MS, Anderson KJ: Ontogeny of the neutral amino acid transporter SAT1/ATA1 in rat brain. Brain Res Dev Brain Res 2003, 143:151-159.
• [25]Berezov TT, Aptekar LS, Zinevich AK: Specificity of glutamine metabolism in pre-tumorous diseases and cancer of the human stomach. Vopr Med Khim 1977, 23:555-558.
• [26]Ogura M, Takarada T, Nakamichi N, Kawagoe H, Sako A, Nakazato R, Yoneda Y: Exacerbated vulnerability to oxidative stress in astrocytic C6 glioma cells with stable overexpression of the glutamine transporter slc38a1. Neurochem Int 2011, 58:504-511.
• [27]Bhat HK, Vadgama JV: Role of estrogen receptor in the regulation of estrogen induced amino acid transport of System A in breast cancer and other receptor positive tumor cells. Int J Mol Med 2002, 9:271-279.
• [28]Dudeck KL, Dudenhausen EE, Chiles TC, Fafournoux P, Kilberg MS: Evidence for inherent differences in the system A carrier from normal and transformed liver tissue. Differential inactivation and substrate protection in membrane vesicles and reconstituted proteoliposomes. J Biol Chem 1987, 262:12565-12569.
• [29]Okada A, Takehara H, Yoshida K, Nishi M, Miyake H, Kita Y, Komi N: Increased aspartate and glutamate levels in both gastric and colon cancer tissues. Tokushima J Exp Med 1993, 40:19-25.
• [30]Medina MA: Glutamine and cancer. J Nutr 2001, 131:2539S-2542S.
• [31]Lu W, Pelicano H, Huang P: Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell 2010, 18:199-200.
• [32]Wise DR, Thompson CB: Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35:427-433.
• [33]National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: gastric cancer, V.1. 2012. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#gastric webcite
• [34]ZhanYQ SXW, Li W, Chen YB, Xu L, Guan YX, Li YF, Xu DZ: Multivariate prognostic analysis in gastric carcinoma patients after radical operation. Ai Zheng 2005, 24(5):596-599.
• [35]Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ: Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 1996, 32A:215-220.